Cefiderocol: a novel siderophore cephalosporin against multi-drug resistant Gram-negative bacilli infections / 生物工程学报
Chinese Journal of Biotechnology
;
(12): 990-1003, 2022.
Article
in Chinese
| WPRIM
| ID: wpr-927758
ABSTRACT
Antimicrobial resistance is one of the critical public health issues in the world. There is an urgent need to develop effective broad-spectrum antibiotics to treat the infection of multi-drug resistant Gram-negative bacilli. Cefiderocol, developed by the Shionogi Inc. in Japan, is a new type of iron carrier cephalosporin antibiotics, which overcomes the drug resistance of Gram-negative bacilli due to the down-regulation of outer membrane pore protein and the up-regulation of efflux pump, and has good stability to serine- and metallo-carbapenemases. This drug has a broad spectrum and strong antibacterial activity against carbapenem-resistant Enterobacteriaceae (CRE), Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia. Cefiderocol can be used to treat complex urinary tract infections (including pyelonephritis), hospital-acquired pneumonia, and ventilator-associated pneumonia. By summarizing the chemical structure, antibacterial mechanism, in vitro antibacterial activity, pharmacokinetics, pharmacodynamics, and clinical treatment of cefiderocol, this review shows the application potential of cefiderocol as a new iron carrier cephalosporin in the treatment of multi-drug resistant Gram-negative bacilli infections.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Microbial Sensitivity Tests
/
Cephalosporins
/
Siderophores
/
Gram-Negative Bacteria
Language:
Chinese
Journal:
Chinese Journal of Biotechnology
Year:
2022
Type:
Article
Similar
MEDLINE
...
LILACS
LIS